
Opinion|Videos|July 1, 2024
Exploring the TROPION-Lung04 Study
Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.
Advertisement
Episodes in this series

- Please review the TROPION-Lung04 study in 1L setting. (
Papadoupoulos et al. WCLC 2023 )
- Briefly outline the study design and key endpoints and discuss the rationale for this treatment approach.
- What implications may these findings have on clinical practice
- Moderator followed up on ADC toxicities
Advertisement
Related to this article

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.

Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.

Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.

TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
3
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5
